Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Westlake University School of Medical, Hangzhou, 310006, China.
Fourth Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310051, China.
Mol Cell Biochem. 2024 Oct;479(10):2615-2636. doi: 10.1007/s11010-023-04893-y. Epub 2023 Dec 5.
Hepatocellular carcinoma (HCC) is the sixed most common malignant tumor in the world. The study for HCC is mired in the predicament confronted with the difficulty of early diagnosis and high drug resistance, the survival rate of patients with HCC being low. Ferroptosis, an iron-dependent cell death, has been discovered in recent years as a cell death means with tremendous potential to fight against cancer. The in-depth researches for iron metabolism, lipid peroxidation and dysregulation of antioxidant defense have brought about tangible progress in the firmament of ferroptosis with more and more results showing close connections between ferroptosis and HCC. The potential role of ferroptosis has been widely used in chemotherapy, immunotherapy, radiotherapy, and nanotherapy, with the development of various new drugs significantly improving the prognosis of patients. Based on the characteristics and mechanisms of ferroptosis, this article further focuses on the main signaling pathways and promising treatments of HCC, envisioning that existing problems in regard with ferroptosis and HCC could be grappled with in the foreseeable future.
肝细胞癌(HCC)是世界上第六种最常见的恶性肿瘤。HCC 的研究陷入了早期诊断困难和药物耐药性高的困境,HCC 患者的生存率较低。近年来,铁依赖性细胞死亡铁死亡作为一种具有巨大抗癌潜力的细胞死亡方式被发现。对铁代谢、脂质过氧化和抗氧化防御失调的深入研究,使铁死亡领域取得了实质性的进展,越来越多的研究结果表明铁死亡与 HCC 密切相关。铁死亡的潜在作用已广泛应用于化疗、免疫治疗、放疗和纳米治疗,各种新药的发展显著改善了患者的预后。基于铁死亡的特点和机制,本文进一步聚焦于 HCC 的主要信号通路和有前途的治疗方法,预计在可预见的未来,现有的铁死亡和 HCC 问题将得到解决。
Mol Cell Biochem. 2024-10
J Cancer Res Clin Oncol. 2018-8-22
Int J Biol Sci. 2024
Hepatol Int. 2024-2
Front Endocrinol (Lausanne). 2024-1-4
Nan Fang Yi Ke Da Xue Xue Bao. 2024-11-20
Mol Neurobiol. 2025-3